person · Reporting owner
YOUNGBLOOD DR KNEELAND
Disclosed activity across 11 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KPET Ultra Paceline CorpKPET · Entity 5979 | Director | March 30, 2026 | March 30, 2026 |
| Light & Wonder, Inc.ASX:LNW · Entity 9758 | Director | June 10, 2026 | June 13, 2026 |
| Nerdy Inc.PACE · Entity 5208 | Director | October 06, 2020 | October 06, 2020 |
| Pharos Capital BDC, Inc.NONE · Entity 168323 | Director · Chief Executive Officer | March 13, 2018 | March 13, 2018 |
| TPG Pace Beneficial Finance Corp.TPGY · Entity 131171 | Director | October 06, 2020 | October 06, 2020 |
| TPG Pace Beneficial II Corp.YTPG · Entity 131170 | Director | April 13, 2021 | April 13, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KPET Ultra Paceline Corp
Report date March 30, 2026 · Filed March 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary Shares, par value $0.0001 per shareSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-30 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The Class B Ordinary Shares are automatically convertible into the Issuer's Class A Ordinary Shares at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, and have no expiration date. The Class B Ordinary Shares are subject to forfeiture under certain circumstances relating to the Reporting Person's service on the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B Ordinary Shares are automatically convertible into the Issuer's Class A Ordinary Shares at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, and have no expiration date. The Class B Ordinary Shares are subject to forfeiture under certain circumstances relating to the Reporting Person's service on the Issuer's Board of Directors.
Light & Wonder, Inc.
Report date June 10, 2026 · Filed June 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,555 |
Reported balance
After 2026-06-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-10 · Exercise / conversion · Acquired 2,391 · Balance 30,555 F1: Shares are held via CHESS Depositary Interests ("CDIs"), which are units of beneficial ownership in shares of common stock of the Company that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty. Limited, a subsidiary of ASX Limited, the company that operates the ASX. Each CDI represents one fully paid share of common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Exercise / conversion · Disposed 2,391 · Balance 0 F2: Represents the vesting of restricted stock units granted on June 10, 2025. The award has fully vested. Each restricted stock unit converted into a share of common stock on a one-for-one basis. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,498 |
Reported balance
After 2026-06-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-10 · Grant · Acquired 2,498 · Balance 2,498 F3: The restricted stock units are scheduled to vest on the earlier of (a) the date of the issuer's 2027 annual meeting of stockholders and (b) June 10, 2027. Each unit converts into a share of common stock on a one-for-one basis. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares are held via CHESS Depositary Interests ("CDIs"), which are units of beneficial ownership in shares of common stock of the Company that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty. Limited, a subsidiary of ASX Limited, the company that operates the ASX. Each CDI represents one fully paid share of common stock.
F2: Represents the vesting of restricted stock units granted on June 10, 2025. The award has fully vested. Each restricted stock unit converted into a share of common stock on a one-for-one basis.
F3: The restricted stock units are scheduled to vest on the earlier of (a) the date of the issuer's 2027 annual meeting of stockholders and (b) June 10, 2027. Each unit converts into a share of common stock on a one-for-one basis.
Nerdy Inc.
Report date October 06, 2020 · Filed October 06, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class F Ordinary Shares, par value $0.0001SEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-10-06 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The reporting person owns 40,000 Class F ordinary shares, par value $0.0001 per share ("Class F Ordinary Shares"), which are convertible into Class A Ordinary Shares, par value $0.0001 per share, as described under the heading "Description of Securities-Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-248594). The Class F Ordinary Shares have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person owns 40,000 Class F ordinary shares, par value $0.0001 per share ("Class F Ordinary Shares"), which are convertible into Class A Ordinary Shares, par value $0.0001 per share, as described under the heading "Description of Securities-Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-248594). The Class F Ordinary Shares have no expiration date.
Pharos Capital BDC, Inc.
Report date March 13, 2018 · Filed March 13, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2018-03-13 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
TPG Pace Beneficial Finance Corp.
Report date October 06, 2020 · Filed October 06, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class F Ordinary Shares, par value $0.0001SEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-10-06 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The reporting person owns 40,000 Class F ordinary shares, par value $0.0001 per share ("Class F Ordinary Shares"), which are convertible into Class A Ordinary Shares, par value $0.0001 per share, as described under the heading "Description of Securities-Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-248595). The Class F Ordinary Shares have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person owns 40,000 Class F ordinary shares, par value $0.0001 per share ("Class F Ordinary Shares"), which are convertible into Class A Ordinary Shares, par value $0.0001 per share, as described under the heading "Description of Securities-Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-248595). The Class F Ordinary Shares have no expiration date.
TPG Pace Beneficial II Corp.
Report date April 13, 2021 · Filed April 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class F Ordinary Shares, par value $0.0001SEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-04-13 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The reporting person owns 40,000 Class F ordinary shares, par value $0.0001 per share ("Class F Ordinary Shares"), which are convertible into Class A Ordinary Shares, par value $0.0001 per share, as described under the heading "Description of Securities-Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333- 254008). The Class F Ordinary Shares have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person owns 40,000 Class F ordinary shares, par value $0.0001 per share ("Class F Ordinary Shares"), which are convertible into Class A Ordinary Shares, par value $0.0001 per share, as described under the heading "Description of Securities-Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333- 254008). The Class F Ordinary Shares have no expiration date.
Past disclosures · reporting ended (5)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Accel Entertainment, Inc.
Report date November 20, 2019 · Filed November 22, 2019
Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class F Ordinary SharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-11-20 · Sale · Disposed 40,000 · Balance 0 F1: Pursuant to the Amended and Restated Memorandum and Articles of Association of TPG Pace Holdings Corp. (renamed as Accel Entertainment, Inc., the "Issuer"), the Class F Ordinary Shares, par value $0.0001 per share, of the Issuer had been automatically convertible into Class A Ordinary Shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Amended and Restated Memorandum and Articles of Association of TPG Pace Holdings Corp. (renamed as Accel Entertainment, Inc., the "Issuer"), the Class F Ordinary Shares, par value $0.0001 per share, of the Issuer had been automatically convertible into Class A Ordinary Shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment.
Core Scientific, Inc./tx
Report date January 23, 2024 · Filed February 16, 2024 · Amendment
Section 16 reporting ended · disclosed 2024-02-16. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2024-01-23 · Disposition to issuer · Disposed 400,038 · Balance 0 F1: On December 21, 2022, Core Scientific, Inc. (the "Issuer") and certain of its affiliates (collectively, the "Debtors") filed voluntary petitions (the "Chapter 11 Cases") in the United States Bankruptcy Court for the Southern District of Texas (the "Bankruptcy Court") seeking relief under Chapter 11 of Title 11 of the United States Code. On January 16, 2024, the Bankruptcy Court entered an order confirming the Debtors' Fourth Amended Joint Chapter 11 Plan of Reorganization of Core Scientific, Inc. and its Affiliated Debtors (with Technical Modifications) (the "Plan"), dated as of January 15, 2024. On January 23, 2024 (the "Effective Date"), the Plan became effective in accordance with its terms and the Debtors emerged from the Chapter 11 Cases. F2: On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the "Old Common Stock"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock and unvested restricted stock units ("RSUs") received new common stock, par value $0.00001 per share at an exchange ratio of 10:1 (the "New Common Stock") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization), F3: (Continued from footnote 2) and, for each share of Old Common Stock, 0.253244 Tranche 1 Warrants and 0.211037 Tranche 2 Warrants (each as defined below). The receipt of the New Common Stock, Tranche 1 Warrants and Tranche 2 Warrants in exchange for Old Common Stock and unvested RSUs was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court. |
| Common Stock, par value $0.00001 per shareSEC Table I · non-derivative | Direct | 40,004 |
Reported balance
After 2024-01-23 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2024-01-23 · Grant · Acquired 40,004 · Balance 40,004 F2: On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the "Old Common Stock"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock and unvested restricted stock units ("RSUs") received new common stock, par value $0.00001 per share at an exchange ratio of 10:1 (the "New Common Stock") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization), F3: (Continued from footnote 2) and, for each share of Old Common Stock, 0.253244 Tranche 1 Warrants and 0.211037 Tranche 2 Warrants (each as defined below). The receipt of the New Common Stock, Tranche 1 Warrants and Tranche 2 Warrants in exchange for Old Common Stock and unvested RSUs was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court. |
| Tranche 1 WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $6.81 · Expires 2027-01-23 | Direct | 50,654 |
Reported balance
After 2024-01-23 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2024-01-23 · Grant · Acquired 50,654 · Balance 50,654 F2: On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the "Old Common Stock"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock and unvested restricted stock units ("RSUs") received new common stock, par value $0.00001 per share at an exchange ratio of 10:1 (the "New Common Stock") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization), F3: (Continued from footnote 2) and, for each share of Old Common Stock, 0.253244 Tranche 1 Warrants and 0.211037 Tranche 2 Warrants (each as defined below). The receipt of the New Common Stock, Tranche 1 Warrants and Tranche 2 Warrants in exchange for Old Common Stock and unvested RSUs was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court. F4: On the Effective Date, pursuant to the terms of the Plan, the Issuer entered into a warrant agreement dated as of January 23, 2024, (the "Warrant Agreement") among the Company and Computershare Inc., a Delaware corporation and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company. Pursuant to the Warrant Agreement, the Issuer was authorized to issue (i) an aggregate of 98,381,418 warrants, each exercisable for one share of New Common Stock (the "Tranche 1 Warrants") and (ii) an aggregate of 81,984,644 warrants, each exercisable for one share of New Common Stock (the "Tranche 2 Warrants"). Each whole Tranche 1 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $6.81 per share (the "Tranche 1 Exercise Price"). F5: (Continued from footnote 4) Each whole Tranche 2 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $0.01 per share at any time following the time the volume weighted average price per share of New Common Stock equals or exceeds $8.72 per share on each trading day for 20 consecutive trading days (the "TEV Triggering Event"). The Tranche 1 Exercise Price and the price per share used to determine a TEV Triggering Event are subject to certain adjustments as set forth in the Warrant Agreement. |
| Tranche 2 WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2029-01-23 | Direct | 42,212 |
Reported balance
After 2024-01-23 transaction · row 4
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 4 · 2024-01-23 · Grant · Acquired 42,212 · Balance 42,212 F2: On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the "Old Common Stock"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock and unvested restricted stock units ("RSUs") received new common stock, par value $0.00001 per share at an exchange ratio of 10:1 (the "New Common Stock") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization), F3: (Continued from footnote 2) and, for each share of Old Common Stock, 0.253244 Tranche 1 Warrants and 0.211037 Tranche 2 Warrants (each as defined below). The receipt of the New Common Stock, Tranche 1 Warrants and Tranche 2 Warrants in exchange for Old Common Stock and unvested RSUs was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court. F4: On the Effective Date, pursuant to the terms of the Plan, the Issuer entered into a warrant agreement dated as of January 23, 2024, (the "Warrant Agreement") among the Company and Computershare Inc., a Delaware corporation and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company. Pursuant to the Warrant Agreement, the Issuer was authorized to issue (i) an aggregate of 98,381,418 warrants, each exercisable for one share of New Common Stock (the "Tranche 1 Warrants") and (ii) an aggregate of 81,984,644 warrants, each exercisable for one share of New Common Stock (the "Tranche 2 Warrants"). Each whole Tranche 1 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $6.81 per share (the "Tranche 1 Exercise Price"). F5: (Continued from footnote 4) Each whole Tranche 2 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $0.01 per share at any time following the time the volume weighted average price per share of New Common Stock equals or exceeds $8.72 per share on each trading day for 20 consecutive trading days (the "TEV Triggering Event"). The Tranche 1 Exercise Price and the price per share used to determine a TEV Triggering Event are subject to certain adjustments as set forth in the Warrant Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 21, 2022, Core Scientific, Inc. (the "Issuer") and certain of its affiliates (collectively, the "Debtors") filed voluntary petitions (the "Chapter 11 Cases") in the United States Bankruptcy Court for the Southern District of Texas (the "Bankruptcy Court") seeking relief under Chapter 11 of Title 11 of the United States Code. On January 16, 2024, the Bankruptcy Court entered an order confirming the Debtors' Fourth Amended Joint Chapter 11 Plan of Reorganization of Core Scientific, Inc. and its Affiliated Debtors (with Technical Modifications) (the "Plan"), dated as of January 15, 2024. On January 23, 2024 (the "Effective Date"), the Plan became effective in accordance with its terms and the Debtors emerged from the Chapter 11 Cases.
F2: On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the "Old Common Stock"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock and unvested restricted stock units ("RSUs") received new common stock, par value $0.00001 per share at an exchange ratio of 10:1 (the "New Common Stock") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization),
F3: (Continued from footnote 2) and, for each share of Old Common Stock, 0.253244 Tranche 1 Warrants and 0.211037 Tranche 2 Warrants (each as defined below). The receipt of the New Common Stock, Tranche 1 Warrants and Tranche 2 Warrants in exchange for Old Common Stock and unvested RSUs was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court.
F4: On the Effective Date, pursuant to the terms of the Plan, the Issuer entered into a warrant agreement dated as of January 23, 2024, (the "Warrant Agreement") among the Company and Computershare Inc., a Delaware corporation and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company. Pursuant to the Warrant Agreement, the Issuer was authorized to issue (i) an aggregate of 98,381,418 warrants, each exercisable for one share of New Common Stock (the "Tranche 1 Warrants") and (ii) an aggregate of 81,984,644 warrants, each exercisable for one share of New Common Stock (the "Tranche 2 Warrants"). Each whole Tranche 1 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $6.81 per share (the "Tranche 1 Exercise Price").
F5: (Continued from footnote 4) Each whole Tranche 2 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $0.01 per share at any time following the time the volume weighted average price per share of New Common Stock equals or exceeds $8.72 per share on each trading day for 20 consecutive trading days (the "TEV Triggering Event"). The Tranche 1 Exercise Price and the price per share used to determine a TEV Triggering Event are subject to certain adjustments as set forth in the Warrant Agreement.
Keenova Therapeutics plc
Report date June 16, 2022 · Filed June 21, 2022
Section 16 reporting ended · disclosed 2022-06-21. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Pace Holdings Corp.
Report date March 10, 2017 · Filed March 14, 2017
Section 16 reporting ended · disclosed 2017-03-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class F Ordinary SharesSEC Table II · derivative / convertible security | IndirectSee Explanation of Responses | 0 |
Reported balance
After 2017-03-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-10 · Disposition to issuer · Disposed 40,000 · Balance 0 F1: In connection with the merger of Pace Holdings Corp. (the "Issuer") with and into New PACE Holdings Corp. and a series of related transactions (collectively, the "Business Combination"), Dr. Kneeland Youngblood disposed of his Class F ordinary shares, par value $0.0001 (the "Class F Shares"), of the Issuer ultimately receiving ordinary shares, par value (euro) 0.10 per share, of Playa Hotels & Resorts N.V. Pursuant to the Amended and Restated Memorandum and Articles of Association of the Issuer, the Class F Shares were to automatically convert into Class A ordinary shares, par value $0.0001, of the Issuer at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment. F2: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that Dr. Youngblood is, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the merger of Pace Holdings Corp. (the "Issuer") with and into New PACE Holdings Corp. and a series of related transactions (collectively, the "Business Combination"), Dr. Kneeland Youngblood disposed of his Class F ordinary shares, par value $0.0001 (the "Class F Shares"), of the Issuer ultimately receiving ordinary shares, par value (euro) 0.10 per share, of Playa Hotels & Resorts N.V. Pursuant to the Amended and Restated Memorandum and Articles of Association of the Issuer, the Class F Shares were to automatically convert into Class A ordinary shares, par value $0.0001, of the Issuer at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment.
F2: Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that Dr. Youngblood is, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities of the Issuer.
TPG Pace Solutions Corp.
Report date December 03, 2021 · Filed December 07, 2021
Section 16 reporting ended · disclosed 2021-12-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class F Ordinary Shares, par value $0.0001SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-12-03 · Disposition to issuer · Disposed 40,000 · Balance 0 F1: Pursuant to the Memorandum and Articles of Association, as amended, of TPG Pace Solutions Corp. (the "Issuer"), the Class F Ordinary Shares, par value $0.0001 per share ("Class F Shares"), of the Issuer, were automatically convertible into Class A Ordinary Shares, par value $0.0001 per share ("Class A Shares"), of the Issuer, on a one-for-one basis, at the time of the Issuer's initial business combination, subject to adjustment. F2: In connection with the merger of the Issuer with and into Vacasa, Inc. ("Vacasa") pursuant to the Business Combination Agreement, as amended, dated as of July 28, 2021, by and among the Issuer, Vacasa and the other parties thereto, the Class F Shares were automatically cancelled, extinguished and converted, on a one-for-one basis, into shares of Class F Common Stock of Vacasa. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Memorandum and Articles of Association, as amended, of TPG Pace Solutions Corp. (the "Issuer"), the Class F Ordinary Shares, par value $0.0001 per share ("Class F Shares"), of the Issuer, were automatically convertible into Class A Ordinary Shares, par value $0.0001 per share ("Class A Shares"), of the Issuer, on a one-for-one basis, at the time of the Issuer's initial business combination, subject to adjustment.
F2: In connection with the merger of the Issuer with and into Vacasa, Inc. ("Vacasa") pursuant to the Business Combination Agreement, as amended, dated as of July 28, 2021, by and among the Issuer, Vacasa and the other parties thereto, the Class F Shares were automatically cancelled, extinguished and converted, on a one-for-one basis, into shares of Class F Common Stock of Vacasa.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 13, 2026 01:57 UTC | Light & Wonder, Inc. ASX:LNW · Entity 9758 | GrantRestricted Stock Units · Derivative | 2,498 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-26-000718 · ownership.xml · derivative · entry 3 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,498 Underlying: Common Stock · 2,498 shares Expires not disclosed F3 · derivative.exercise_price: The restricted stock units are scheduled to vest on the earlier of (a) the date of the issuer's 2027 annual meeting of stockholders and (b) June 10, 2027. Each unit converts into a share of common stock on a one-for-one basis. F3 · derivative.exercise_date: The restricted stock units are scheduled to vest on the earlier of (a) the date of the issuer's 2027 annual meeting of stockholders and (b) June 10, 2027. Each unit converts into a share of common stock on a one-for-one basis. F3 · derivative.expiration_date: The restricted stock units are scheduled to vest on the earlier of (a) the date of the issuer's 2027 annual meeting of stockholders and (b) June 10, 2027. Each unit converts into a share of common stock on a one-for-one basis. Read SEC document |
| June 10, 2026 Filed Jun 13, 2026 01:57 UTC | Light & Wonder, Inc. ASX:LNW · Entity 9758 | Exercise / conversionRestricted Stock Units · Derivative | 2,391 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-26-000718 · ownership.xml · derivative · entry 2 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,391 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Represents the vesting of restricted stock units granted on June 10, 2025. The award has fully vested. Each restricted stock unit converted into a share of common stock on a one-for-one basis. F2 · derivative.exercise_date: Represents the vesting of restricted stock units granted on June 10, 2025. The award has fully vested. Each restricted stock unit converted into a share of common stock on a one-for-one basis. F2 · derivative.expiration_date: Represents the vesting of restricted stock units granted on June 10, 2025. The award has fully vested. Each restricted stock unit converted into a share of common stock on a one-for-one basis. Read SEC document |
| June 10, 2026 Filed Jun 13, 2026 01:57 UTC | Light & Wonder, Inc. ASX:LNW · Entity 9758 | Exercise / conversionCommon Stock | 2,391 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-26-000718 · ownership.xml · nonDerivative · entry 1 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares are held via CHESS Depositary Interests ("CDIs"), which are units of beneficial ownership in shares of common stock of the Company that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty. Limited, a subsidiary of ASX Limited, the company that operates the ASX. Each CDI represents one fully paid share of common stock. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 20:27 UTC | Light & Wonder, Inc. LNW · Entity 9758 | GrantRestricted Stock Units · Derivative | 2,391 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-25-000503 · form4.xml · derivative · entry 1 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,391 Underlying: Common Stock · 2,391 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units are scheduled to vest on the earlier of (a) the date of the issuer's 2026 annual meeting of stockholders and (b) June 10, 2026. Each unit converts into a share of common stock on a one-for-one basis. F1 · derivative.exercise_date: The restricted stock units are scheduled to vest on the earlier of (a) the date of the issuer's 2026 annual meeting of stockholders and (b) June 10, 2026. Each unit converts into a share of common stock on a one-for-one basis. F1 · derivative.expiration_date: The restricted stock units are scheduled to vest on the earlier of (a) the date of the issuer's 2026 annual meeting of stockholders and (b) June 10, 2026. Each unit converts into a share of common stock on a one-for-one basis. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 20:26 UTC | Light & Wonder, Inc. LNW · Entity 9758 | Exercise / conversionRestricted Stock Units · Derivative | 2,159 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-25-000476 · form4.xml · derivative · entry 2 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,159 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents the vesting of restricted stock units granted on June 5, 2024. The award has fully vested. Each restricted stock unit converted into a share of common stock on a one-for-one basis. F1 · derivative.exercise_date: Represents the vesting of restricted stock units granted on June 5, 2024. The award has fully vested. Each restricted stock unit converted into a share of common stock on a one-for-one basis. F1 · derivative.expiration_date: Represents the vesting of restricted stock units granted on June 5, 2024. The award has fully vested. Each restricted stock unit converted into a share of common stock on a one-for-one basis. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 20:26 UTC | Light & Wonder, Inc. LNW · Entity 9758 | Exercise / conversionCommon Stock | 2,159 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-25-000476 · form4.xml · nonDerivative · entry 1 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,164 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2024 Filed Jun 10, 2024 22:42 UTC | Light & Wonder, Inc. LNW · Entity 9758 | Exercise / conversionRestricted Stock Units · Derivative | 2,093 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-24-000878 · form4.xml · derivative · entry 2 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,093 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents vesting of one-fourth of restricted stock units granted on June 10, 2020. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis. F1 · derivative.exercise_date: Represents vesting of one-fourth of restricted stock units granted on June 10, 2020. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis. F1 · derivative.expiration_date: Represents vesting of one-fourth of restricted stock units granted on June 10, 2020. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis. Read SEC document |
| June 10, 2024 Filed Jun 10, 2024 22:42 UTC | Light & Wonder, Inc. LNW · Entity 9758 | Exercise / conversionCommon Stock | 2,093 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-24-000878 · form4.xml · nonDerivative · entry 1 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2024 Filed Jun 7, 2024 20:54 UTC | Light & Wonder, Inc. LNW · Entity 9758 | Exercise / conversionRestricted Stock Units · Derivative | 3,320 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-24-000863 · form4.xml · derivative · entry 3 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,320 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Represents the vesting of restricted stock units granted on June 7, 2023. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis. F2 · derivative.exercise_date: Represents the vesting of restricted stock units granted on June 7, 2023. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis. F2 · derivative.expiration_date: Represents the vesting of restricted stock units granted on June 7, 2023. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis. Read SEC document |
| June 07, 2024 Filed Jun 7, 2024 20:54 UTC | Light & Wonder, Inc. LNW · Entity 9758 | Exercise / conversionCommon Stock | 3,320 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-24-000863 · form4.xml · nonDerivative · entry 1 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:54 UTC | Light & Wonder, Inc. LNW · Entity 9758 | GrantRestricted Stock Units · Derivative | 2,159 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-24-000863 · form4.xml · derivative · entry 2 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,159 Underlying: Common Stock · 2,159 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units are scheduled to vest on the earlier of (a) the date of the issuer's 2025 annual meeting of stockholders and (b) June 5, 2025. Each unit converts into a share of common stock on a one-for-one basis. F1 · derivative.exercise_date: The restricted stock units are scheduled to vest on the earlier of (a) the date of the issuer's 2025 annual meeting of stockholders and (b) June 5, 2025. Each unit converts into a share of common stock on a one-for-one basis. F1 · derivative.expiration_date: The restricted stock units are scheduled to vest on the earlier of (a) the date of the issuer's 2025 annual meeting of stockholders and (b) June 5, 2025. Each unit converts into a share of common stock on a one-for-one basis. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:05 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | GrantCommon Stock, par value $0.00001 per share | 400,038 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-007642 · ownership.xml · nonDerivative · entry 2 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,038 F2 · price: On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the "Old Common Stock"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock received their pro rata share of new common stock, par value $0.00001 per share ("New Common Stock") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization). The receipt of the New Common Stock in exchange for Old Common Stock was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:05 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | Disposition to issuerCommon Stock, par value $0.0001 per share | 400,038 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-007642 · ownership.xml · nonDerivative · entry 1 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On December 21, 2022, Core Scientific, Inc. (the "Issuer") and certain of its affiliates (collectively, the "Debtors") filed voluntary petitions (the "Chapter 11 Cases") in the United States Bankruptcy Court for the Southern District of Texas (the "Bankruptcy Court") seeking relief under Chapter 11 of Title 11 of the United States Code. On January 16, 2024, the Bankruptcy Court entered an order confirming the Debtors' Fourth Amended Joint Chapter 11 Plan of Reorganization of Core Scientific, Inc. and its Affiliated Debtors (with Technical Modifications) (the "Plan"), dated as of January 15, 2024. On January 23, 2024 (the "Effective Date"), the Plan became effective in accordance with its terms and the Debtors emerged from the Chapter 11 Cases. F2 · price: On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the "Old Common Stock"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock received their pro rata share of new common stock, par value $0.00001 per share ("New Common Stock") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization). The receipt of the New Common Stock in exchange for Old Common Stock was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court. Read SEC document |
| January 23, 2024 Filed Feb 16, 2024 16:18 UTC Amendment | Core Scientific, Inc./tx CORZ · Entity 389 | GrantTranche 2 Warrants · Derivative | 42,212 | Not disclosed Strike: $0.01 | Not disclosed |
DisclosureSEC source: 0000950170-24-016389 · ownership.xml · derivative · entry 4 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,212 Underlying: Common Stock, par value $0.00001 per share · 42,212 shares Expires 2029-01-23 F2 · price: On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the "Old Common Stock"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock and unvested restricted stock units ("RSUs") received new common stock, par value $0.00001 per share at an exchange ratio of 10:1 (the "New Common Stock") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization), F3 · price: (Continued from footnote 2) and, for each share of Old Common Stock, 0.253244 Tranche 1 Warrants and 0.211037 Tranche 2 Warrants (each as defined below). The receipt of the New Common Stock, Tranche 1 Warrants and Tranche 2 Warrants in exchange for Old Common Stock and unvested RSUs was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court. F4 · price: On the Effective Date, pursuant to the terms of the Plan, the Issuer entered into a warrant agreement dated as of January 23, 2024, (the "Warrant Agreement") among the Company and Computershare Inc., a Delaware corporation and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company. Pursuant to the Warrant Agreement, the Issuer was authorized to issue (i) an aggregate of 98,381,418 warrants, each exercisable for one share of New Common Stock (the "Tranche 1 Warrants") and (ii) an aggregate of 81,984,644 warrants, each exercisable for one share of New Common Stock (the "Tranche 2 Warrants"). Each whole Tranche 1 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $6.81 per share (the "Tranche 1 Exercise Price"). F5 · price: (Continued from footnote 4) Each whole Tranche 2 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $0.01 per share at any time following the time the volume weighted average price per share of New Common Stock equals or exceeds $8.72 per share on each trading day for 20 consecutive trading days (the "TEV Triggering Event"). The Tranche 1 Exercise Price and the price per share used to determine a TEV Triggering Event are subject to certain adjustments as set forth in the Warrant Agreement. F4 · derivative.exercise_date: On the Effective Date, pursuant to the terms of the Plan, the Issuer entered into a warrant agreement dated as of January 23, 2024, (the "Warrant Agreement") among the Company and Computershare Inc., a Delaware corporation and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company. Pursuant to the Warrant Agreement, the Issuer was authorized to issue (i) an aggregate of 98,381,418 warrants, each exercisable for one share of New Common Stock (the "Tranche 1 Warrants") and (ii) an aggregate of 81,984,644 warrants, each exercisable for one share of New Common Stock (the "Tranche 2 Warrants"). Each whole Tranche 1 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $6.81 per share (the "Tranche 1 Exercise Price"). F5 · derivative.exercise_date: (Continued from footnote 4) Each whole Tranche 2 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $0.01 per share at any time following the time the volume weighted average price per share of New Common Stock equals or exceeds $8.72 per share on each trading day for 20 consecutive trading days (the "TEV Triggering Event"). The Tranche 1 Exercise Price and the price per share used to determine a TEV Triggering Event are subject to certain adjustments as set forth in the Warrant Agreement. Read SEC document |
| January 23, 2024 Filed Feb 16, 2024 16:18 UTC Amendment | Core Scientific, Inc./tx CORZ · Entity 389 | GrantTranche 1 Warrants · Derivative | 50,654 | Not disclosed Strike: $6.81 | Not disclosed |
DisclosureSEC source: 0000950170-24-016389 · ownership.xml · derivative · entry 3 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,654 Underlying: Common Stock, par value $0.00001 per share · 50,654 shares Expires 2027-01-23 F2 · price: On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the "Old Common Stock"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock and unvested restricted stock units ("RSUs") received new common stock, par value $0.00001 per share at an exchange ratio of 10:1 (the "New Common Stock") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization), F3 · price: (Continued from footnote 2) and, for each share of Old Common Stock, 0.253244 Tranche 1 Warrants and 0.211037 Tranche 2 Warrants (each as defined below). The receipt of the New Common Stock, Tranche 1 Warrants and Tranche 2 Warrants in exchange for Old Common Stock and unvested RSUs was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court. F4 · price: On the Effective Date, pursuant to the terms of the Plan, the Issuer entered into a warrant agreement dated as of January 23, 2024, (the "Warrant Agreement") among the Company and Computershare Inc., a Delaware corporation and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company. Pursuant to the Warrant Agreement, the Issuer was authorized to issue (i) an aggregate of 98,381,418 warrants, each exercisable for one share of New Common Stock (the "Tranche 1 Warrants") and (ii) an aggregate of 81,984,644 warrants, each exercisable for one share of New Common Stock (the "Tranche 2 Warrants"). Each whole Tranche 1 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $6.81 per share (the "Tranche 1 Exercise Price"). F5 · price: (Continued from footnote 4) Each whole Tranche 2 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $0.01 per share at any time following the time the volume weighted average price per share of New Common Stock equals or exceeds $8.72 per share on each trading day for 20 consecutive trading days (the "TEV Triggering Event"). The Tranche 1 Exercise Price and the price per share used to determine a TEV Triggering Event are subject to certain adjustments as set forth in the Warrant Agreement. F4 · derivative.exercise_date: On the Effective Date, pursuant to the terms of the Plan, the Issuer entered into a warrant agreement dated as of January 23, 2024, (the "Warrant Agreement") among the Company and Computershare Inc., a Delaware corporation and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company. Pursuant to the Warrant Agreement, the Issuer was authorized to issue (i) an aggregate of 98,381,418 warrants, each exercisable for one share of New Common Stock (the "Tranche 1 Warrants") and (ii) an aggregate of 81,984,644 warrants, each exercisable for one share of New Common Stock (the "Tranche 2 Warrants"). Each whole Tranche 1 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $6.81 per share (the "Tranche 1 Exercise Price"). F5 · derivative.exercise_date: (Continued from footnote 4) Each whole Tranche 2 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $0.01 per share at any time following the time the volume weighted average price per share of New Common Stock equals or exceeds $8.72 per share on each trading day for 20 consecutive trading days (the "TEV Triggering Event"). The Tranche 1 Exercise Price and the price per share used to determine a TEV Triggering Event are subject to certain adjustments as set forth in the Warrant Agreement. Read SEC document |
| January 23, 2024 Filed Feb 16, 2024 16:18 UTC Amendment | Core Scientific, Inc./tx CORZ · Entity 389 | GrantCommon Stock, par value $0.00001 per share | 40,004 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-016389 · ownership.xml · nonDerivative · entry 2 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,004 F2 · price: On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the "Old Common Stock"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock and unvested restricted stock units ("RSUs") received new common stock, par value $0.00001 per share at an exchange ratio of 10:1 (the "New Common Stock") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization), F3 · price: (Continued from footnote 2) and, for each share of Old Common Stock, 0.253244 Tranche 1 Warrants and 0.211037 Tranche 2 Warrants (each as defined below). The receipt of the New Common Stock, Tranche 1 Warrants and Tranche 2 Warrants in exchange for Old Common Stock and unvested RSUs was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court. Read SEC document |
| January 23, 2024 Filed Feb 16, 2024 16:18 UTC Amendment | Core Scientific, Inc./tx CORZ · Entity 389 | Disposition to issuerCommon Stock, par value $0.0001 per share | 400,038 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-016389 · ownership.xml · nonDerivative · entry 1 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On December 21, 2022, Core Scientific, Inc. (the "Issuer") and certain of its affiliates (collectively, the "Debtors") filed voluntary petitions (the "Chapter 11 Cases") in the United States Bankruptcy Court for the Southern District of Texas (the "Bankruptcy Court") seeking relief under Chapter 11 of Title 11 of the United States Code. On January 16, 2024, the Bankruptcy Court entered an order confirming the Debtors' Fourth Amended Joint Chapter 11 Plan of Reorganization of Core Scientific, Inc. and its Affiliated Debtors (with Technical Modifications) (the "Plan"), dated as of January 15, 2024. On January 23, 2024 (the "Effective Date"), the Plan became effective in accordance with its terms and the Debtors emerged from the Chapter 11 Cases. F2 · price: On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the "Old Common Stock"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock and unvested restricted stock units ("RSUs") received new common stock, par value $0.00001 per share at an exchange ratio of 10:1 (the "New Common Stock") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization), F3 · price: (Continued from footnote 2) and, for each share of Old Common Stock, 0.253244 Tranche 1 Warrants and 0.211037 Tranche 2 Warrants (each as defined below). The receipt of the New Common Stock, Tranche 1 Warrants and Tranche 2 Warrants in exchange for Old Common Stock and unvested RSUs was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court. Read SEC document |
| June 12, 2023 Filed Jun 12, 2023 23:00 UTC | Light & Wonder, Inc. LNW · Entity 9758 | Exercise / conversionRestricted Stock Units · Derivative | 1,928 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-23-000656 · form4.xml · derivative · entry 4 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,928 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Represents vesting of one-fourth of restricted stock units granted on June 12, 2019. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis. F2 · derivative.exercise_date: Represents vesting of one-fourth of restricted stock units granted on June 12, 2019. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis. F2 · derivative.expiration_date: Represents vesting of one-fourth of restricted stock units granted on June 12, 2019. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis. Read SEC document |
| June 12, 2023 Filed Jun 12, 2023 23:00 UTC | Light & Wonder, Inc. LNW · Entity 9758 | Exercise / conversionCommon Stock | 1,928 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-23-000656 · form4.xml · nonDerivative · entry 2 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,592 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2023 Filed Jun 12, 2023 23:00 UTC | Light & Wonder, Inc. LNW · Entity 9758 | Exercise / conversionRestricted Stock Units · Derivative | 2,093 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-23-000656 · form4.xml · derivative · entry 3 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,093 Underlying: Common Stock · 2,093 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents vesting of one-fourth of restricted stock units granted on June 10, 2020. The balance of the award is scheduled to vest on June 10, 2024. Each unit converts into a share of common stock on a one-for-one basis. F1 · derivative.exercise_date: Represents vesting of one-fourth of restricted stock units granted on June 10, 2020. The balance of the award is scheduled to vest on June 10, 2024. Each unit converts into a share of common stock on a one-for-one basis. F1 · derivative.expiration_date: Represents vesting of one-fourth of restricted stock units granted on June 10, 2020. The balance of the award is scheduled to vest on June 10, 2024. Each unit converts into a share of common stock on a one-for-one basis. Read SEC document |
| June 10, 2023 Filed Jun 12, 2023 23:00 UTC | Light & Wonder, Inc. LNW · Entity 9758 | Exercise / conversionCommon Stock | 2,093 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-23-000656 · form4.xml · nonDerivative · entry 1 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 21:22 UTC | Light & Wonder, Inc. LNW · Entity 9758 | Exercise / conversionRestricted Stock Units · Derivative | 3,840 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-23-000640 · form4.xml · derivative · entry 3 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,840 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Represents vesting of restricted stock units granted on June 8, 2022. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis. F2 · derivative.exercise_date: Represents vesting of restricted stock units granted on June 8, 2022. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis. F2 · derivative.expiration_date: Represents vesting of restricted stock units granted on June 8, 2022. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 21:22 UTC | Light & Wonder, Inc. LNW · Entity 9758 | Exercise / conversionCommon Stock | 3,840 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-23-000640 · form4.xml · nonDerivative · entry 1 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 21:22 UTC | Light & Wonder, Inc. LNW · Entity 9758 | GrantRestricted Stock Units · Derivative | 3,320 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-23-000640 · form4.xml · derivative · entry 2 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,320 Underlying: Common Stock · 3,320 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units are scheduled to vest on June 7, 2024. Each unit converts into a share of common stock on a one-for-one basis. F1 · derivative.exercise_date: The restricted stock units are scheduled to vest on June 7, 2024. Each unit converts into a share of common stock on a one-for-one basis. F1 · derivative.expiration_date: The restricted stock units are scheduled to vest on June 7, 2024. Each unit converts into a share of common stock on a one-for-one basis. Read SEC document |
| June 13, 2022 Filed Sep 6, 2022 18:32 UTC | Core Scientific, Inc./tx CORZ · Entity 389 | GrantCommon Stock | 400,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-048849 · doc4.xml · nonDerivative · entry 1 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,038 F1 · shares: Represents a restricted stock unit ("RSU") grants. The RSUs vest in four equal annual installments commencing January 19, 2023, provided that the Reporting Person continues to provide service to the Issuer on each vesting date. Read SEC document |
| June 12, 2022 Filed Jun 14, 2022 20:13 UTC | Light & Wonder, Inc. LNW · Entity 9758 | Exercise / conversionRestricted Stock Units · Derivative | 1,927 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-22-000709 · form4.xml · derivative · entry 2 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,928 Underlying: Common Stock · 1,927 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents vesting of one-fourth of restricted stock units granted on June 12, 2019. The balance of the award is scheduled to vest on June 12, 2023. Each unit converts into a share of common stock on a one-for-one basis. F1 · derivative.exercise_date: Represents vesting of one-fourth of restricted stock units granted on June 12, 2019. The balance of the award is scheduled to vest on June 12, 2023. Each unit converts into a share of common stock on a one-for-one basis. F1 · derivative.expiration_date: Represents vesting of one-fourth of restricted stock units granted on June 12, 2019. The balance of the award is scheduled to vest on June 12, 2023. Each unit converts into a share of common stock on a one-for-one basis. Read SEC document |
| June 12, 2022 Filed Jun 14, 2022 20:13 UTC | Light & Wonder, Inc. LNW · Entity 9758 | Exercise / conversionCommon Stock | 1,927 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-22-000709 · form4.xml · nonDerivative · entry 1 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,731 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2022 Filed Jun 10, 2022 20:53 UTC | Light & Wonder, Inc. LNW · Entity 9758 | Exercise / conversionRestricted Stock Units · Derivative | 2,093 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-22-000691 · form4.xml · derivative · entry 5 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,186 Underlying: Common Stock · 2,093 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Represents vesting of one-fourth of restricted stock units granted on June 10, 2020. The balance of the award is scheduled to vest in two equal installments on each of June 10, 2023 and June 10, 2024. Each unit converts into a share of common stock on a one-for-one basis. F3 · derivative.exercise_date: Represents vesting of one-fourth of restricted stock units granted on June 10, 2020. The balance of the award is scheduled to vest in two equal installments on each of June 10, 2023 and June 10, 2024. Each unit converts into a share of common stock on a one-for-one basis. F3 · derivative.expiration_date: Represents vesting of one-fourth of restricted stock units granted on June 10, 2020. The balance of the award is scheduled to vest in two equal installments on each of June 10, 2023 and June 10, 2024. Each unit converts into a share of common stock on a one-for-one basis. Read SEC document |
| June 10, 2022 Filed Jun 10, 2022 20:53 UTC | Light & Wonder, Inc. LNW · Entity 9758 | Exercise / conversionCommon Stock | 2,093 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-22-000691 · form4.xml · nonDerivative · entry 2 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:53 UTC | Light & Wonder, Inc. LNW · Entity 9758 | Exercise / conversionRestricted Stock Units · Derivative | 2,763 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-22-000691 · form4.xml · derivative · entry 4 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,763 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Represents vesting of restricted stock units granted on June 9, 2021. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis. F2 · derivative.exercise_date: Represents vesting of restricted stock units granted on June 9, 2021. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis. F2 · derivative.expiration_date: Represents vesting of restricted stock units granted on June 9, 2021. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:53 UTC | Light & Wonder, Inc. LNW · Entity 9758 | Exercise / conversionCommon Stock | 2,763 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-22-000691 · form4.xml · nonDerivative · entry 1 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,711 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:53 UTC | Light & Wonder, Inc. LNW · Entity 9758 | GrantRestricted Stock Units · Derivative | 3,840 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-22-000691 · form4.xml · derivative · entry 3 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,840 Underlying: Common Stock · 3,840 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units are scheduled to vest on June 8, 2023. Each unit converts into a share of common stock on a one-for-one basis. F1 · derivative.exercise_date: The restricted stock units are scheduled to vest on June 8, 2023. Each unit converts into a share of common stock on a one-for-one basis. F1 · derivative.expiration_date: The restricted stock units are scheduled to vest on June 8, 2023. Each unit converts into a share of common stock on a one-for-one basis. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 16:40 UTC | TPG Pace Solutions Corp. TPGS · Entity 132718 | Disposition to issuerClass F Ordinary Shares, par value $0.0001 · Derivative | 40,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-147236 · tm2134770-4_4seq1.xml · derivative · entry 1 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares, par value $0.0001 · 40,000 shares Expires not disclosed F1 · derivative.exercise_price: Pursuant to the Memorandum and Articles of Association, as amended, of TPG Pace Solutions Corp. (the "Issuer"), the Class F Ordinary Shares, par value $0.0001 per share ("Class F Shares"), of the Issuer, were automatically convertible into Class A Ordinary Shares, par value $0.0001 per share ("Class A Shares"), of the Issuer, on a one-for-one basis, at the time of the Issuer's initial business combination, subject to adjustment. F2 · price: In connection with the merger of the Issuer with and into Vacasa, Inc. ("Vacasa") pursuant to the Business Combination Agreement, as amended, dated as of July 28, 2021, by and among the Issuer, Vacasa and the other parties thereto, the Class F Shares were automatically cancelled, extinguished and converted, on a one-for-one basis, into shares of Class F Common Stock of Vacasa. F1 · derivative.exercise_date: Pursuant to the Memorandum and Articles of Association, as amended, of TPG Pace Solutions Corp. (the "Issuer"), the Class F Ordinary Shares, par value $0.0001 per share ("Class F Shares"), of the Issuer, were automatically convertible into Class A Ordinary Shares, par value $0.0001 per share ("Class A Shares"), of the Issuer, on a one-for-one basis, at the time of the Issuer's initial business combination, subject to adjustment. F1 · derivative.expiration_date: Pursuant to the Memorandum and Articles of Association, as amended, of TPG Pace Solutions Corp. (the "Issuer"), the Class F Ordinary Shares, par value $0.0001 per share ("Class F Shares"), of the Issuer, were automatically convertible into Class A Ordinary Shares, par value $0.0001 per share ("Class A Shares"), of the Issuer, on a one-for-one basis, at the time of the Issuer's initial business combination, subject to adjustment. Read SEC document |
| June 12, 2021 Filed Jun 15, 2021 20:35 UTC | Light & Wonder, Inc. SGMS · Entity 9758 | Exercise / conversionRestricted Stock Units · Derivative | 1,928 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-21-000657 · form4.xml · derivative · entry 2 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,855 Underlying: Common Stock · 1,928 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents vesting of one-fourth of restricted stock units granted on June 12, 2019. The balance of the award is scheduled to vest in two installments on June 12, 2022 (1,927 units) and June 12, 2023 (1,928 units). Each unit converts into a share of common stock on a one-for-one basis. F1 · derivative.exercise_date: Represents vesting of one-fourth of restricted stock units granted on June 12, 2019. The balance of the award is scheduled to vest in two installments on June 12, 2022 (1,927 units) and June 12, 2023 (1,928 units). Each unit converts into a share of common stock on a one-for-one basis. F1 · derivative.expiration_date: Represents vesting of one-fourth of restricted stock units granted on June 12, 2019. The balance of the award is scheduled to vest in two installments on June 12, 2022 (1,927 units) and June 12, 2023 (1,928 units). Each unit converts into a share of common stock on a one-for-one basis. Read SEC document |
| June 12, 2021 Filed Jun 15, 2021 20:35 UTC | Light & Wonder, Inc. SGMS · Entity 9758 | Exercise / conversionCommon Stock | 1,928 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-21-000657 · form4.xml · nonDerivative · entry 1 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 20:35 UTC | Light & Wonder, Inc. SGMS · Entity 9758 | Exercise / conversionRestricted Stock Units · Derivative | 2,093 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-21-000629 · form4.xml · derivative · entry 3 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,279 Underlying: Common Stock · 2,093 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Represents vesting of one-fourth of restricted stock units granted on June 10, 2020. The balance of the award is scheduled to vest in three equal installments on each of June 10, 2022, June 10, 2023 and June 10, 2024. Each unit converts into a share of common stock on a one-for-one basis. F2 · derivative.exercise_date: Represents vesting of one-fourth of restricted stock units granted on June 10, 2020. The balance of the award is scheduled to vest in three equal installments on each of June 10, 2022, June 10, 2023 and June 10, 2024. Each unit converts into a share of common stock on a one-for-one basis. F2 · derivative.expiration_date: Represents vesting of one-fourth of restricted stock units granted on June 10, 2020. The balance of the award is scheduled to vest in three equal installments on each of June 10, 2022, June 10, 2023 and June 10, 2024. Each unit converts into a share of common stock on a one-for-one basis. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 20:35 UTC | Light & Wonder, Inc. SGMS · Entity 9758 | Exercise / conversionCommon Stock | 2,093 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-21-000629 · form4.xml · nonDerivative · entry 1 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 20:35 UTC | Light & Wonder, Inc. SGMS · Entity 9758 | GrantRestricted Stock Units · Derivative | 2,763 | $0.00 | $0.00 |
DisclosureSEC source: 0000950157-21-000629 · form4.xml · derivative · entry 2 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,763 Underlying: Common Stock · 2,763 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units are scheduled to vest on June 9, 2022. Each unit converts into a share of common stock on a one-for-one basis. F1 · derivative.exercise_date: The restricted stock units are scheduled to vest on June 9, 2022. Each unit converts into a share of common stock on a one-for-one basis. F1 · derivative.expiration_date: The restricted stock units are scheduled to vest on June 9, 2022. Each unit converts into a share of common stock on a one-for-one basis. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 16:13 UTC | Keenova Therapeutics plc MNKKQ · Entity 28960 | SaleOrdinary Shares | 38,300 | $0.13 | $5,040.28 |
DisclosureSEC source: 0000950138-20-000457 · edgar.xml · nonDerivative · entry 1 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price represents a weighted average. The shares were sold in multiple transactions at prices ranging from $0.12 to $0.14, inclusive. Dr. Youngblood will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range. Read SEC document |
| June 12, 2020 Filed Jun 12, 2020 20:37 UTC | Light & Wonder, Inc. SGMS · Entity 9758 | Exercise / conversionRestricted Stock Units · Derivative | 1,927 | $0.00 | $0.00 |
DisclosureSEC source: 0000750004-20-000089 · wf-form4_159199425311426.xml · derivative · entry 3 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,783 Underlying: Common Stock · 1,927 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Represents vesting of one-fourth of restricted stock units granted on June 12, 2019. The balance of the award is scheduled to vest in three installments on June 12, 2021 (1,928 shares), June 12, 2022 (1,927 shares) and June 12, 2023 (1,928 shares). Each unit converts into a share of common stock on a one-for-one basis. F2 · derivative.exercise_date: Represents vesting of one-fourth of restricted stock units granted on June 12, 2019. The balance of the award is scheduled to vest in three installments on June 12, 2021 (1,928 shares), June 12, 2022 (1,927 shares) and June 12, 2023 (1,928 shares). Each unit converts into a share of common stock on a one-for-one basis. F2 · derivative.expiration_date: Represents vesting of one-fourth of restricted stock units granted on June 12, 2019. The balance of the award is scheduled to vest in three installments on June 12, 2021 (1,928 shares), June 12, 2022 (1,927 shares) and June 12, 2023 (1,928 shares). Each unit converts into a share of common stock on a one-for-one basis. Read SEC document |
| June 12, 2020 Filed Jun 12, 2020 20:37 UTC | Light & Wonder, Inc. SGMS · Entity 9758 | Exercise / conversionCommon Stock | 1,927 | $0.00 | $0.00 |
DisclosureSEC source: 0000750004-20-000089 · wf-form4_159199425311426.xml · nonDerivative · entry 1 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:37 UTC | Light & Wonder, Inc. SGMS · Entity 9758 | GrantRestricted Stock Units · Derivative | 8,372 | $0.00 | $0.00 |
DisclosureSEC source: 0000750004-20-000089 · wf-form4_159199425311426.xml · derivative · entry 2 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,372 Underlying: Common Stock · 8,372 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units are scheduled to vest in four equal annual installments beginning on June 10, 2021. Each unit converts into a share of common stock on a one-for-one basis. F1 · derivative.exercise_date: The restricted stock units are scheduled to vest in four equal annual installments beginning on June 10, 2021. Each unit converts into a share of common stock on a one-for-one basis. F1 · derivative.expiration_date: The restricted stock units are scheduled to vest in four equal annual installments beginning on June 10, 2021. Each unit converts into a share of common stock on a one-for-one basis. Read SEC document |
| May 13, 2020 Filed May 15, 2020 16:59 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 8,729 | $2.96 | $25,837.84 |
DisclosureSEC source: 0000950138-20-000269 · edgar.xml · nonDerivative · entry 1 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,300 Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 16:17 UTC | Accel Entertainment, Inc. ACEL · Entity 4999 | SaleClass F Ordinary Shares · Derivative | 40,000 | $10.22 | $408,800.00 |
DisclosureSEC source: 0000899243-19-027961 · doc4.xml · derivative · entry 1 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Former Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 40,000 shares Expires not disclosed F1 · derivative.exercise_price: Pursuant to the Amended and Restated Memorandum and Articles of Association of TPG Pace Holdings Corp. (renamed as Accel Entertainment, Inc., the "Issuer"), the Class F Ordinary Shares, par value $0.0001 per share, of the Issuer had been automatically convertible into Class A Ordinary Shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment. F1 · derivative.exercise_date: Pursuant to the Amended and Restated Memorandum and Articles of Association of TPG Pace Holdings Corp. (renamed as Accel Entertainment, Inc., the "Issuer"), the Class F Ordinary Shares, par value $0.0001 per share, of the Issuer had been automatically convertible into Class A Ordinary Shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment. F1 · derivative.expiration_date: Pursuant to the Amended and Restated Memorandum and Articles of Association of TPG Pace Holdings Corp. (renamed as Accel Entertainment, Inc., the "Issuer"), the Class F Ordinary Shares, par value $0.0001 per share, of the Issuer had been automatically convertible into Class A Ordinary Shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment. Read SEC document |
| June 12, 2019 Filed Jun 12, 2019 22:41 UTC | Light & Wonder, Inc. SGMS · Entity 9758 | GrantRestricted Stock Units · Derivative | 7,710 | $0.00 | $0.00 |
DisclosureSEC source: 0000750004-19-000061 · wf-form4_156037927321233.xml · derivative · entry 1 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,710 Underlying: Common Stock · 7,710 shares Expires not disclosed F1 · derivative.exercise_price: The restricted stock units are scheduled to vest beginning on June 12, 2020 (1,927 shares) and the balance in three installments on June 12, 2021 (1,928 shares), June 12, 2022 (1,927 shares) and June 12, 2023 (1,928 shares). Each unit converts into a share of common stock on a one-for-one basis. F1 · derivative.exercise_date: The restricted stock units are scheduled to vest beginning on June 12, 2020 (1,927 shares) and the balance in three installments on June 12, 2021 (1,928 shares), June 12, 2022 (1,927 shares) and June 12, 2023 (1,928 shares). Each unit converts into a share of common stock on a one-for-one basis. F1 · derivative.expiration_date: The restricted stock units are scheduled to vest beginning on June 12, 2020 (1,927 shares) and the balance in three installments on June 12, 2021 (1,928 shares), June 12, 2022 (1,927 shares) and June 12, 2023 (1,928 shares). Each unit converts into a share of common stock on a one-for-one basis. Read SEC document |
| May 15, 2019 Filed May 17, 2019 07:16 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 19,396 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000318 · edgar.xml · nonDerivative · entry 2 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,029 F1 · shares: Consists of restricted stock units that vest in their entirety as of the date of the Company's 2020 Annual General Meeting. The restricted stock units settle in ordinary shares upon vesting. Read SEC document |
| May 15, 2019 Filed May 17, 2019 07:16 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 8,527 | $15.21 | $129,695.67 |
DisclosureSEC source: 0000950138-19-000318 · edgar.xml · nonDerivative · entry 1 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,633 Read SEC document |
| August 06, 2018 Filed Aug 8, 2018 20:34 UTC | Light & Wonder, Inc. SGMS · Entity 9758 | GrantEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $37.35 | $0.00 |
DisclosureSEC source: 0000750004-18-000178 · wf-form4_153376047447761.xml · derivative · entry 1 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-08-06 F1 · derivative.exercise_date: The stock options are scheduled to become exercisable in four equal annual installments beginning on August 6, 2019. Read SEC document |
| May 16, 2018 Filed May 18, 2018 16:53 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 18,947 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000431 · edgar.xml · nonDerivative · entry 1 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,160 F1 · shares: Consists of restricted stock units that vest in their entirety as of the date of the Company's 2019 Annual General Meeting. The restricted stock units settle in ordinary shares upon vesting. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 16:37 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 2,576 | $15.68 | $40,391.68 |
DisclosureSEC source: 0000950138-18-000218 · edgar.xml · nonDerivative · entry 1 YOUNGBLOOD DR KNEELAND · CIK 0001137820 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,213 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.